Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors
Table 2
Analysis of predictors of PFS.
Variable
Kaplan–Meier analysis
Cox multivariate regression analysis
HR
95% CI
HR
95% CI
Age
0.80
0.49–1.29
0.34
Sex
0.66
0.38–1.13
0.16
ECOG PS
0.80
0.41–1.58
0.49
BMI
0.59
0.36–0.96
0.030
Smoking
0.91
0.571.48
0.71
Distant metastasis
0.82
0.49–1.36
0.42
Treatment lines
1.05
0.58–1.91
0.86
Bone metastasis
0.38
0.13–1.07
0.0037
0.25–1.43
0.25
Treatment regimen (anti-PD-1/PD-L1)
2.44
1.06–5.63
0.003
2.85
1.47–5.52
0.0051
WBC (cutoff = 8.19 × 109/L)
1.89
0.86–4.14
0.038
0.78–3.84
0.18
ALC (cutoff = 0.635 × 109/L)
2.61
1.39–4.91
0.017
0.92–13.69
0.06
PLT (cutoff = 201.5 × 109/L)
2.02
1.24–3.26
0.003
3.13
1.78–5.52
0.0008
LDH (cutoff = 227 U/L)
1.63
0.99–2.67
0.047
1.85
1.06–3.24
0.0315
Indicators with statistical significance; —Represents no usability data; WBC, white blood cell; LDH, lactate dehydrogenase; PLT, platelet; ALC, absolute lymphocyte count; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1; BMI: body mass index.
